Aging and Metabolic Changes in COPD Patients
Introduction: Exploring Clinical Heterogeneity and Metabolic Changes in COPD
COPD shows great clinical heterogeneity, with various subgroups of patients being characterized through sharing clinical or biological features (phenotypes, treatable traits).
However, other relevant characteristics have not been sufficiently investigated such as age or sex, that also appear to influence the clinical expression of the disease.
Our objective was to analyze the differentially expressed metabolites between COPD patients and healthy subjects and the influence of aging and sex.
Methods: Metabolomic Analysis Techniques for Studying Metabolic Changes in COPD
Metabolomic analysis (LC-MS/MS) was carried out in plasma from 95 healthy controls (52±11 yrs., 44% women) and 105 patients (57±13 yrs., 47% women, FEV1 58±22% pred.) randomly chosen from BIOMEPOC and EARLY-COPD cohorts.
Results: Key Metabolic Differences in COPD Patients: Fatty Acids and Amino Acids
Up to 14 metabolites showed differences between both groups, amongst them highlighting decreases in fatty acids as well as increases in both amino acids and components of the Krebs cycle in COPD patients.
These differences were far more pronounced in males.
When analyzing the effect of aging, the differences in metabolism between both groups showed a clear inflection point at the beginning of the sixth decade of life, suggesting a switch to an abnormally increased protein catabolism in COPD patients at this age.
Conclusions: Impact of Metabolic Changes in COPD on Protein Metabolism and Energy Production
Thus, we conclude that COPD fundamentally affects protein metabolism and energy production, with the first of these processes being highly dependent on early aging.
Authors
J.G. Gea, C. Casadevall, P. Nebot, C.J. Enríquez Rodríguez, M.R. Faner, B.G. Cosio, N. Haro , S. Pascual-Guardia, G. Peces-Barba, E. Monsó, J.L. Lopez-Campos, E. Barreiro, A. Agusti, O. Pozo, on behalf of BIOMEPOC and EARLY-COPD groups
Read more details at
Categorías asociadas al artículo
Noticias relacionadas
El Dr. Álvar Agustí advierte de la “epoc Young” y pide realizar espirometrías en la infancia y juventud
El neumólogo e investigador de Barcelona Respiratory Network pide realizar este tipo de pruebas para detectar precozmente esta patología
Circulating Biomarkers in Young Individuals with Low Peak FEV1s
It is now well established that there is a range of lung function tralectories throughout the life course.
Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime…
Artículos
Estudios
- 759397·Alberto Sandiumenge et Al.-Systemic Inflammation Differences in Brain-vs. Circulatory-Dead Donors: Impact on Lung Transplant Recipients
- 759578·Alberto Papi et Al.-Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY
- 759689·Kilian Vellvé et Alt.- Pulmonary vascular reactivity in growth restricted fetuses using computational modelling and machine learning analysis of fetal Doppler waveforms.
- 769273· Singh D, Criner GJ, Agustí A et al. Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
- 769685·Nuria Olvera et Al.- Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD
Imagen desarrollada DALL·E y Canva
